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Abstract 
ROP is an important cause of childhood blindness world-wide. Visual loss from ROP can be 
avoided through good neonatal care, and screening plus early treatment of infants at risk. 
ROP Screening guidelines used in high-income countries are not appropriate for detecting all 
ROP in middle-income countries, where more mature infants are at risk. Therefore, the first 
South African ROP screening guideline was published in 2013. Screening requirements are 
highly dependent on the quality of care provided and may vary widely between neonatal 
units. In addition, screening more mature infants may not be feasible where resources are 
limited. Therefore, ROP screening guidelines should be based on local data. The objectives of  
this research was to determine optimal screening criteria for retinopathy of prematurity at 
Tygerberg Children’s Hospital (TCH), South Africa and to explore the workload implications 
of applying different criteria. 
A complete literature review was performed and is summarized in section B of this 
dissertation. The study protocol (Section A) was drafted and sent for approval. The ethics 
committee of the Faculties of Medicine of both the University of Cape Town [924/2014] and 
Stellenbosch University [S14/10/218], as well as Tygerberg Hospital, approved the research. 
The complete study results are discussed in the manuscript (Section C), which will be 
submitted for publication in the South African Medical Journal. A short summary of the 
study follows below. 
This was a cross-sectional study based on an existing database analysis. The study population 
was premature infants screened for ROP at TCH, from 1 January 2009 to 31 December 2014. 
Eligible infants with missing information were excluded from the analysis. The statistical 
analysis included logistic regression for prediction and classification. The predictors were 
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birthweight (BW) and gestational age (GA), and the main endpoints were clinically 
significant ROP (CSROP) and Type 1 ROP (T1ROP).  
The cohort of 1104 infants had a median GA at birth of 28 weeks (IQR 27-29; range 24-37) 
and median BW of 930 g (IQR 820-1040; range 523-2600). ROP (any ROP) was found in 
33% (369/1104), clinically CSROP was found in 9% (100/1104) and T1ROP in 2.45% 
(27/1104). The 27 infants with T1ROP all received laser therapy and were 29 weeks or 1060g 
and smaller (Median GA: 27 weeks (IQR26-28; range 24-29) and median BW: 815 g (IQR 
763-940; range 640-1060)). The most mature infant in the dataset with CSROP that did not
require intervention had a GA of 31 weeks and BW of 1530 g. 
Among the 621 infants, for whom both GA and BW were recorded, GA was not a 
significantly better predictor of CSROP than BW (p=0.521). Neither were using GA in 
addition to BW in the prediction model better than using BW (p=0.181) alone. The number of 
screening examinations required was inversely correlated with GA and BW (spearman 
correlation coefficient -0.20 and -0.27; p<0.001). The median number of screening 
examinations per infant was 2 (IQR 1-3; range 1-11). The number needed to screen to 
identify one infant needing treatment was 41. Screening 41 infants entailed 83 screening 
examination visits, four screening hours, one technician and three doctors. 
The main study points are: 
 The prevalence of treatable T1ROP was low (2.45% (27/1104)).
 BW measurements were as good as GA in predicting CSROP, and are useful in our
setting, where reliable GA estimates are often unattainable.
 Screening infants with a GA of ≤28weeks or BW of <1000 g would have detected all
infants requiring treatment in the dataset, but missed two outliers with CSROP.
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 Detection of the outliers would have been achieved with the wider screening criteria
of GA of >32 weeks or BW>1500g only.
 Screening larger infants requires less work than screening smaller infants.
 Missing data limits the interpretation of the study results.
In conclusion, the avoidance of unnecessary ROP screening examinations is important since 
it is resource intensive. However, making the local screening criteria narrower on the basis of 
a limited evidence base may be dangerous. More research is required to develop screening 
criteria for the identification of more mature infants at risk of ROP in resource limited 
settings. 
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Background and Rationale 
ROP is an important cause of childhood blindness world-wide. ROP accounted for 10.6% of 
blindness in children in schools for the blind in South Africa.  Visual loss from ROP can be 
avoided through good neonatal care and screening plus early treatment of infants at risk of 
ROP. Screening guidelines are based on birth weight (BW) and gestational age (GA) values 
that detect infants requiring examination. Screening criteria used in the developed world are 
not appropriate for the detection of all infants at risk of ROP in middle-income countries, 
since higher BW infants in these countries may also develop ROP. Additional ROP screening 
of higher BW infants may not be feasible in resource limited settings or necessary in all 
middle-income institutions. Therefore, ROP screening guidelines should be based on local 
data. The purpose of this research is to determine optimal screening criteria for retinopathy of  
prematurity at Tygerberg Children’s Hospital (TCH), South Africa and to explore the 
workload implications of applying different criteria. 
Objectives 
1. To determine the BW and GA cut-off values that maximizes the sensitivity of the 
prediction of ROP. 
2. To determine the total number of screening examinations required at different cut-off 
values of birth weight and gestational age. 
3. To determine the number of examinations required to identify one infant needing treatment 
according to screening criteria recommended by the study data. 
Study Population and Eligibility Criteria 
The study population is premature infants born in the drainage area of TCH, Western Cape, 
South Africa. All premature infants screened for ROP at TCH neonatal units from 1 January 
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2009 to 31 December 2014 for whom the required data are available on the existing ROP 
database or retrieved from hospital folders will be included in the study. Eligible infants with 
irretrievable missing information will be excluded from the study.   
Study Design 
This is a consecutive patient cross-sectional study based on an existing database analysis and 
retrospective folder review. The variables required for the data analysis for each infant is 
routinely recorded in the hospital folder on a ROP screening examination form and in the 
ROP screening Microsoft Excel database on the day of examination. The statistical analysis 
will include logistic regression for prediction and classification. The predictors are BW, GA 
and the main endpoint is clinically significant ROP as measured by the gold standard.  
Sample size 
A large existing database (all 2009-2014 TCH ROP screening examinations) will be 
statistically analyzed; the sample size is therefore fixed to number of infants with information 
recorded in the database. 
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BACKGROUND AND RATIONALE 
Retinopathy of prematurity (ROP) is a vision-threatening vasoproliferative condition of 
premature infants worldwide. In addition to blindness, ROP is associated with an increased 
incidence of refractive errors, amblyopia, strabismus, cataracts and glaucoma.1 Among the 
numerous associations described in the literature, the main accepted risk factors for ROP are 
low gestational age(GA), low birth weight(BW) poor oxygen management (ie. fluctuating 
hypoxia/hyperoxia/lack of monitoring) and lack of antenatal steroids. The mainstay of control 
of visual loss from ROP lies in primary prevention of the condition through good neonatal 
care and programs of secondary prevention whereby babies at risk of ROP are examined to 
detect those needing prompt intervention for treatable stages of the disease.2 Most ROP 
Screening guidelines use BW and GA to identify infants needing examination, because these 
are major risk factors, are relatively straight forward to measure and are recorded routinely. 
Infants who meet the screening criteria are referred for indirect ophthalmoscopy by a trained 
ophthalmologist. Although indirect ophthalmoscopy is considered the gold standard for 
detecting ROP, retina photography with a retina camera (Retcam) has been shown to be a 
reliable, accurate and cost-effective alternative method of ROP detection. 4-6 Detected ROP is 
classified according to the International Classification of Retinopathy of Prematurity 
(ICROP) system7 (Appendix B) and these infants are followed until ROP has progressed to 
treatable stages or has resolved spontaneously. Cryotherapy reduced the rate of adverse 
outcome in threshold ROP by 50%.8-9 Prompt treatment of type one high risk pre-threshold 
ROP with laser photocoagulation further improved short and long term visual outcomes and 
is now considered the standard of care for ROP treatment. 10-11 Early ROP screening and laser 
treatment is a resource intensive preventative strategy, but because of the high lifetime costs 
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of severe visual impairment it has been shown to be highly cost-effective in first world 
countries.12-13  
ROP is responsible for blindness in an estimated 50 000 children throughout the world3 and is 
now often the leading cause of blindness in children in middle-income countries.14 The 
proportion of blindness due to ROP has been shown to be associated with the infant mortality 
rate (IMR) at country level.15 In countries with high IMRs, premature infants do not survive. 
In those with a low IMR ROP blindness is controlled through adequate ROP prevention 
programmes. In countries with IMRs in the mid-range (9-60/1000 live births) ROP is 
emerging as a major cause of blindness because improved neonatal care causes an increased 
premature infant survival rate which is disproportionate to primary and secondary ROP 
preventative strategy implementation. This phenomenon is known as the ‘third epidemic of 
ROP’ and is attributed to both an increase in premature infant survival (the cause of the 
‘second epidemic’) and poor oxygen management (the cause of the ‘first epidemic’) in 
neonatal intensive care units (NICUs). Due to these oxygen management inadequacies in 
middle-income country NICUs larger infants than in high-income NICUs may be at risk and 
require screening. 2,15 However, facilities lacking the staff and equipment for continuous 
infant oxygen monitoring might struggle to allocate resources towards ROP screening 
expansion or even establishment. 
South Africa has an infant mortality rate of 53/1000 live births16 and has become part of the 
‘third epidemic of ROP’. 17 An estimated 16 000 infants in South Africa are at risk of ROP 
and require screening each year. 17-18 In 1995, ROP accounted for 10.6% of blindness in 
children in schools for the blind in South Africa.19 The reported ROP incidence among 
infants with birth weights less than 1500g in South African academic centres remain low, 
with the incidence of any ROP ranging from 16.3-24.5% and clinically significant ROP 
VSSELS001: ROP Screening Criteria and Work Load Implications at TCH 
14 
(CSROP) ranging from 1.56-4.4%.20-23 Those with sight threatening ROP requiring treatment 
range from 0.6-2.9%.18
The first South African guideline for the prevention, screening and treatment of ROP was 
published last year.17 It recommends the screening of infants with a GA<32weeks or a 
BW<1500g. Since larger middle-income country infants (GAs: 32-35weeks; BWs: 1500g-
2000g) may be at risk of ROP2, screening of infants with birth weights up to 2000g with 
additional features associated with an increased risk of ROP (poor oxygen monitoring, 
cardiac arrest, multiple blood transfusions, exchange transfusion, severe HIE, family history 
of HIE) is also recommended. Developing screening guidelines that is appropriate for all in 
institutions within a country is challenging since quality of NICU care and therefore ROP 
screening requirements are highly unit dependent.3 Screening higher weight infants may not 
be feasible in units where resources are limited. Most level 2 hospital NICUs in South Africa, 
where larger infants are likely to be at risk of ROP, do not even have access to screening 
facilities. 17 On the contrary, screening larger infants in tertiary institutions in South Africa 
with high quality neonatal care may be an inappropriate application of scarce resource. 
Ideally, criteria and guidelines should be based on local evidence of the population of babies 
at risk of ROP, and these can be modified over time.2
Tygerberg Children’s Hospital (TCH) reported a prevalence of any ROP of 31.1% and 
CSROP of 7.1 % among preterm infants ventilated for respiratory distress (1986-1987)24 and 
a prevalence of any ROP of 21.8% and CSROP of 4.4% of preterm infants treated 
exclusively with non-invasive ventilation in the first week of life (2009-2010).20 Only 1.5% 
of the latter cohort required laser therapy and no screened infants with BWs greater than 
1250g had CSROP. The results from these subgroup analyses are instructive but insufficient 
to inform local screening policy and resource allocation. A focused analysis of the existing 
TCH ROP screening database is needed to determine optimal screening criteria for 
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retinopathy of prematurity at TCH and to explore the workload implications of using 
different BW and GA cut-off values. This work will set a platform for on-going surveillance 
and further research towards cost-effective intervention and scarce resource distribution. 
OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS 
Overall Aim:  
To identify optimal screening criteria for retinopathy of prematurity at Tygerberg 
Children’s Hospital(TCH), South Africa and to explore the workload implications of 
applying different criteria.  
Primary objective: 
To determine the BW (measured routinely at birth in grams) cut-off value and GA (as 
estimated using the date of last normal menstruation (LNMD), early ultra sound (EUS) or 
the New BALLARD score) cut-off value that maximizes the sensitivity of the prediction 
of ROP (as measured by the gold standard). 
Secondary objectives: 
 To determine the relationship between birth weight and number of screening 
examinations. 
 To determine the total number of screening examinations required at different cut-
off values of birth weight and gestational age. 
 To determine the number of examinations required to identify one infant needing 
treatment according to screening criteria recommended by the study data. 
METHODS 
Study design 
This is a consecutive patient cross-sectional study based on an existing database analysis 
and retrospective folder review. The variables required for the data analysis (BW, GA and 
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ROP zone and stage) for each infant is routinely recorded in the hospital folder on a ROP 
screening examination form (Appendix C) and in the ROP Screening Microsoft Excel 
database on the day of examination.      
Setting and study population 
The study population is premature infants born in the drainage area of TCH, Western 
Cape, South Africa.  
Subjects 
Premature infants managed at a TCH neonatal unit and referred for a ROP screening 
examination between 1 January 2009 and 31 December 2014. 
Selection, Inclusion and Exclusion criteria 
All premature infants screened for ROP at TCH neonatal units from 1 January 2009 to 31 
December 2014 for whom the required data are available on the existing ROP database or 
retrieved from hospital folders. Eligible babies with irretrievable missing information will be 
excluded from the study.   
Measures  
Explanatory variables 
BW (continuous), GA(continuous), Number of Screening Examinations (continuous), 
Sex(binary), Ward(categorical), Time of Examination(continuous).  
Outcome variables  
ROP zone (right eye), ROP stage (right eye), ROP zone (left eye), ROP stage (left eye). 
These categorical variables will be converted to the following binary (yes/no) variables: Any 
ROP, Clinically Significant ROP (CSROP), Type 1 ROP (treatable ROP) and LASER 
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treatment. CSROP is defined as ROP involving zone I, any stage 3 ROP or plus disease 
associated with any stage ROP in any zone. Type 1 ROP is defined as any stage zone I ROP 
with plus disease, zone I stage 3 with or without plus disease or zone II stage 2 or 3 ROP with 
plus disease. 
 
Data management plan 
Data collection an entering 
The data are routinely collected by neonatologists and ophthalmologists and entered in an 
Microsoft Excel database which is kept by the paediatric ophthalmology consultant who 
heads the ROP screening programme at TCH. Since the data are collected routinely by 
various members of the ROP screening team it may contain a considerable degree of missing 
data and errors. Some data entering restrictions are in place to minimize recording errors.    
Data storage and validation 
Once the planned study receives ethics approval, the data sheet (1 January 2009 to 31 
December 2014) will be cleaned and exported to STATA 13 for data exploration and 
statistical analysis. The extent of missing data and recording errors will be examined. Should 
these be non-random, hospital records will be accessed to retrieve or validate data. Once data 
collection is complete each infant will be assigned a unique study number for patient 
confidentiality purposes. The TCH ROP Screening Criteria Study database will be stored on 
the author’s personal computer which is password protected. 
Statistical considerations, sample size and power 
A large existing database (all 2009-2014 TCH ROP screening examinations) will be 
statistically analyzed; the sample size is therefore fixed to number of infants with information 
recorded in the database. The 2009-2010 data alone was sufficient to show a significant 
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association between BW and CSROP (p=0.023, unadjusted odds ratio (OR) not reported) in a 
recent ROP risk factor finding study 20 (using the same dataset). The adjusted association was 
1.002 (CI: 1.000 – 1.004; p=0.038; adjusted for severe apnoea and gender), which is small 
and just significant. This study included only infants who were treated exclusively with non-
invasive ventilation in the first week of life. Among these 356 babies screened between 2009 
and 2010 the prevalence of any ROP was 21.8% and CSROP 4.4%. 
Data analysis plan 
Descriptive Analysis: 
Basic data exploration (univariate analysis) will be performed. Mean and standard deviations 
will be reported for normally distributed numerical variables and medians and interquartile 
ranges for skew data. Categorical data will be reported as proportions. The study sample 
characteristics will be summarized in tables and illustrated graphically (stratification 
according to number of examinations, ward and the various endpoints will be included). 
Analytic Analysis: 
Objectives with Analysis Plans 
Objective 1: To determine the BW and GA cut-off values that maximizes the sensitivity of 
the prediction.  
Endpoint: CSROP 
Analysis: Logistic regression for prediction and classification (ROC curves) 
Objective 2: To determine the relationship between birth weight and number of screening 
examinations.  
Endpoint: Number of screening examinations per premature infant 
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Analysis: Bivariate analysis of two continuous variables (correlation and scatterplots) 
Objective 3: To determine the total number of screenings required at different cut-off 
values of birth weight.  
Endpoint: Total number of screening visits 
Analysis: Subgroup analysis (exclude those not meeting the criteria). Descriptive 
statistics. 
Objective 4: To determine the number of screening examinations required to identify one 
infant needing treatment according to screening criteria recommended by the 
study data. 
Endpoint: Number of screening examinations 
Analysis: Subgroup analysis (exclude those not meeting the criteria). Descriptive 
statistics. 
Ethical considerations 
Previous research protocols for retrospective studies on the existing ROP database were 
granted ethics approval by the Stellenbosch University in the past: N11-03-082 and S13-10-
178. 
Informed consent 
Application for a waiver of informed parental consent 
The study involves the retrospective analysis of the large ROP Screening database (2009-
2014). The study subjects are premature infants who all received the TCH ROP screening and 
treatment standard of care. Contacting each infant’s parent to gain informed consent to access 
and publish recorded data will not be feasible and may compromise the consecutive patient 
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cross-sectional design required for the diagnostic accuracy study. Parent contact details are 
not recorded in the database. Accessing this information via individual folder review will be 
time consuming, contact details are not recorded reliably and may have changed without 
notice and the study budget and calendar cannot allow for contacting parents.  
This is retrospective, non-experimental, no-harm child research and will generate 
generalizable knowledge likely to minimize risk in local ROP screening and treatment 
programmes. 
Confidentiality 
Each infant in the TCH ROP Screening database will be given a unique study identity 
number. The infants’ identities will not be exposed during data analysis and report. The study 
database will be stored on the PI’s personal computer which is password protected. 
Standard of care 
All infants meeting the screening criteria (BW <1500 or GA < 32 weeks) and those with 
higher birth weights at increased risk for ROP are referred for early ROP screening and 
treatment. Examination and staging of infants are done according to the International 
Classification of Retinopathy of Prematurity (2005 revision)7 (Appendix B) by a trained 
ophthalmologist using a 28-dioptre condensing lens and an indirect ophthalmoscope (and/or 
specialist interpretation of retcam fundal photography). Infants are examined from 31 weeks 
corrected GA (4 weeks after birth) and then 1 - 3 weekly until vascularization of zone 3 is 
completed or the corrected GA of 41 weeks is reached. Infants with treatable stages of ROP 
(Type 1 ROP) receive laser therapy within 72 hours of diagnosis. 
Conflict of interest 
The investigator declares no conflict of interest. 
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STUDY LIMITATIONS 
Since this study involves the analysis of data collected as part of routine care (not under 
rigorous study circumstances) measurement error, data entry errors and missing data may 
threaten the internal validity of the results. For example, GA is estimated in three different 
ways (LNMD, EUS and/or the New Ballard score25) but the database does not discriminate 
which method was used for the recorded value or why. Since the routine of care was applied 
to all infants referred for ROP screening we hope that potential errors outlined above 
occurred at random. Non-random missing data or spurious results may necessitate a 
retrospective folder review to retrieve or validate the database information. This process may 
not be feasible to complete within the timeframe allowed since the existing database is very 
large (2009-2014). In this case the data for 2013-2014 only will be retrieved and/or validated. 
 
 




This is a straight forward, low cost study with a reasonable timeframe. Co-supervisor of this 
study and UCT MPH Clinical Research Tract student supervisor, Professor Landon Myer, 
confirmed the feasibility of the proposed study. 
FUTURE DIRECTIONS 
In addition to informing local ROP screening and treatment policy, this work will identify 
areas for improvement in current routine ROP screening data management and can create a 
platform for ongoing ROP surveillance and important further research in cost-effective ROP 
detection.  
STUDY TEAM and INSTITUTIONAL RESEARCH ENVIRONMENT 
The author/principle investigator is a MPH (clinical research tract) student with sufficient 
epidemiology and biostatistics knowledge to complete this study successfully. The 
supervisors are experienced researchers and experts in their fields. Strong research support 
structures for developing researchers exist at both the UCT School of Public Health and 
Stellenbosch University/TCH Centre for Evidence Based Health Care. 
 
 




TCH ROP Screening Criteria Study Budget 
Personnel Compensation 
Investigators The PI is a student and the supervisors are university/hospital 
staff (provide research supervision routinely) 
Research Assistant* R 3 000 – R 10 000  
Consultation services 
Statistical Support The PI has biostats III level training and additional statistical 
support is offered free of charge by School of Public Health 
staff to their students. 
Computer and Software 
Laptop The PI’s personal equipment and software will be used for 
data storage and analysis. External Hard drive 
STATA 13 The University of Cape Town is a STATA license holder and 
provides student access in designated computer laboratories. 
Other direct Costs 
Phone Broadband/wireless internet access is available at PI home 
and office. Paperwork and phone call communication will be 




Ethics review Sponsored for students 
Publication The PI plans to publish in the South African Medical 
Journal. No costs were involved with recent previous 
publications in this journal. 
 
Justification of budget 
This student study is not funded. Costs will be kept to a minimum and covered by the PI.  
* Should research assistantship be required for missing data collection or data validation the 
cost will be covered by the Division of Ophthalmology research fund and the PI. 
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OBJECTIVES OF THE LITERATURE REVIEW:  
The first objective of this literature review was to present a short up-to-date overview of the 
complex disease entity, ROP. Secondly I aimed to discuss ROP as public health issue. 
Burden of disease, preventative strategies, organisation of case detection and care, cost 
effectiveness of interventions and the issues regarding the setup and improvement of ROP 
programmes. Finally, this review describes the gaps in the literature and rationale for the 
work presented in this dissertation.  
LITERATURE SEARCH STRATEGY:  
A search of the PubMed database was performed using the following search terms 
“retinopathy of prematurity”, ”ROP”, “ROP risk factors”, ”ROP Screening”, “ROP 
programmes”, “ROP guidelines”, “ROP treatment”, “VEGF”, ”gestational age”, 
“birthweight”, “retina camera”, “retcam”, ”telemedicine”, “postnatal growth”, ”cost 
effectiveness”, “incidence”, “burden “and “workload” in various combinations . Abstracts 
were reviewed and relevant English full text articles were retrieved. Mainly articles published 
in high impact journals in the past 10 years were selected, but highly regarded older 
publications were also included. The reference lists of the articles were then used to obtain 
further relevant literature. 
 
SUMMARTY OF THE LITERATURE: 
Background 
Retinopathy of prematurity is a vision-threatening vasoproliferative disorder that occurs in 
premature infants.(1) It has become a leading cause of childhood blindness world-wide. In 
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addition to blindness, ROP is associated with an increased incidence of refractive errors, 
amblyopia, strabismus, cataracts and glaucoma.(2)  
The first, second and third ROP epidemic 
In the late 1940s, ROP appeared suddenly in preterm infants. The disorder, initially called 
retrolental fibroplasia, was characterised by a complete retinal detachment behind the lens.(3) 
The cause of this ‘first epidemic’ of retinopathy of prematurity was the use of supplemental 
oxygen in closed incubators, which helped improve the survival of infants, but also 
contributed to blindness.(3, 4) Today, uncontrolled oxygen supplementation remains a major 
risk factor for ROP, and optimum oxygenation to balance the risk of ROP against improved 
survival is still unsettled.(3) Low infant gestational age at birth and low birth weight are other 
major risk factors for ROP. A ‘second epidemic’ of ROP arose due to first world technology 
allowing smaller and smaller premature infants to survive. The current ‘third epidemic’ of 
ROP is attributed to both the survival of more extremely premature babies, and the survival 
of babies in settings that lack the resources to prevent and manage the associated retinopathy.  
ROP burden 
Worldwide, 10% of births occur preterm (before the gestational age of 37 full weeks).(5) 
Recent global estimates of the incidence of blindness and severe visual impairment from 
ROP are much higher than formerly.(6) It was updated from 50 000 children under 15 years 
of age (estimated largely from blind school surveys and dubbed the ‘third epidemic’ of ROP) 
(7, 8), to a more alarming annual incidence of 20 000 infants blind from ROP and a further 12 
300 with mild or moderate visual impairment.(9) This estimate comes from more rigorous 
methodology based on the published incidence of preterm birth, mortality rates and the 
proportion of ROP requiring treatment, and suggests the greatest burden of disease is now in 
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the rapidly developing economies of India, China and South East Asia (middle-income 
countries).(6) 
Pre-term birth is the most common cause of neonatal death and the proportion of blindness 
due to ROP has been shown to be associated with the infant mortality rate (IMR) at country 
level.(10) In low-income countries with high IMRs, premature infants do not survive. In 
high-income counties with a low IMR, ROP blindness is controlled through adequate ROP 
prevention programmes. In middle-income countries with IMRs in the mid-range (9-60/1000 
live births) ROP is emerging as a major cause of blindness, because improved neonatal care 
causes an increased premature infant survival rate, which is disproportionate to primary and 
secondary ROP preventative strategy implementation.  
A comparison of the burden of ROP between countries is difficult because of substantial 
variability in study designs, gestational ages of included infants, survival rates and treatments 
used. As shown in table one, severe ROP prevalence estimates from population-based studies 
vary even among countries with similar neonatal intensive care facilities.(3) In addition, Zin 
et al. showed that the ROP burden can vary among neonatal units within one city.(8) Sweden 
has a register (SWEDROP) for all children screened for ROP, which is used to measure 
incidence.(11) Data from this registry show that the incidence of ROP did not change 
substantially over time in this first world setting. This may be due to an increased survival of 
very immature infants at high risk for the disease balanced against improved neonatal 
intensive care. (3) 
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Table 1. ROP estimates in countries with similar neonatal intensive care facilities 





Sweden Austeng et al., 2009 <27 weeks 73% (368/506) 35%(176/506) 
Norway Markestad et al.,2005 <28 weeks 33% (95/290) - 




Darlow et al., 2005 <29 weeks - 10%(203/2105) 
Austria Weber et al., 2005 <27 weeks - 16% (50/316) 
Finland Tommiska et al., 
2007 




The two phase hypothesis for ROP pathogenesis  
Currently the pathogenesis of ROP is best explained by the “two phase hypothesis”. In phase 
1, suppression of growth factors due to hyperoxia and loss of the maternal-foetal interaction 
result in an arrest of retinal vascularisation. Subsequently in phase 2, the increasingly 
metabolic active, yet poorly vascularised, retina becomes hypoxic, stimulating growth factor-
induced vasoproliferation.(3) So first insults arrest normal retinal neurovascular development, 
then pathological compensatory mechanisms lead to abnormal retinal vascularisation. The 
transition between phase 1 and 2 seems to depend on the post menstrual age of the infant 
independent of the postnatal age, which points to an association with programmed timing of 
development and disease pathogenesis.(3)  
ROP Risk factors 
Among the numerous associations described in the literature, the main accepted risk factors 
for ROP are low gestational age(GA) at birth, low birth weight(BW) for gestational age and 
poor oxygen management (i.e. fluctuating hypoxia/hyperoxia/lack of monitoring). 
Gestational age and birth weight  
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Both GA and BW are related to the extent of immaturity of the retina and its vulnerability to 
insult. Low gestational age increases the duration of an infant’s exposure to adverse postnatal 
insults and the lower the GA and BW, the more profound the loss of factors normally 
provided by the intrauterine environment.(3) When very preterm infants are born with a 
weight appropriate for gestational age, birthweight is likely to be a proxy for gestational age 
and not an independent risk factor.(12)  However both GA and BW are considered major risk 
factors for ROP and used in ROP screening criteria and prediction models. A low BW for GA 
(i.e. intra-uterine growth restriction) may be associated with an increased risk of ROP 
(particularly in infants older than 29 weeks GA at birth) but more research is required to 
establish this association. GA, BW and intra-uterine factors are fixed at birth, then postnatal 
factors further influence retina vascularisation. 
Oxygen 
Oxygen supplementation is a known risk factor for ROP since the first wave of ROP, but 
teasing out at which concentrations it is harmful or beneficial in the preterm infant is an 
enduring challenge. The use of 100% oxygen made even some mature preterm babies blind 
during the first ROP epidemic and even room air can lead to hyperoxia compared with the 
intrauterine environment (where mean oxygen pressure is less than 50 mm Hg during the 
second half of pregnancy).(13) On the other hand, oxygen restriction to 50% of inspired O2, 
resulted  in 16 infant deaths per case of blindness averted.(14) Furthermore, Hellström et 
al.(3) point out that preterm infant oxygen requirements may be different in the two phases of 
ROP. In phase 1 high and fluctuating oxygen concentrations acts as an insult that arrests 
normal retina vascularisation, while in phase 2 the relative hypoxic retina requires higher 
oxygen concentrations due to poor vascularization. Oxygen saturation targets are discussed 
further under ROP related blindness control. 
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Other risk factors 
Low Serum IGF-1 is strongly associated with poor postnatal weight gain and ROP in 
premature infants. (13) Postnatal weight gain is used in various models to predict the risk of 
severe ROP in premature infants.(14-16) Hyperglycaemia, neonatal infections, blood 
transfusions, genetic factors, Caucasian race and male gender are associated with ROP but 
not established risk factors.(3) 
ROP related blindness control 
Much severe ROP is preventable, but to achieve this, good organisation of neonatal care on a 
regional basis, a focus on implementing evidence-based practices and ongoing quality 
assurance and audit are required.(15, 16)The mainstay of control of visual loss from ROP lies 
in primary prevention of the condition through good neonatal care and programs of secondary 
prevention whereby babies at risk of ROP are examined to detect those needing prompt 
intervention for treatable stages of the disease. 
Oxygen saturation targets 
The optimum oxygenation to balance the risk of ROP against improved survival is still 
unclear.(3) To resolve this issue, five randomised controlled trials in infants with gestation 
<29 weeks have compared a SpO2 target of 85–89% with 91–95% and will pool the results in 
an individual patient data meta-analysis (the Neonatal Oxygenation Prospective Meta- 
analysis Collaboration (NeOProM)).(17) Some NeOProM trials (the SUPPORT and the 
BOOST II Australia and UK) reported that the lower target was associated with a small but 
significant increase in mortality at hospital discharge.(6) An interim meta-analysis of 
mortality data confirms this, being 19.3% versus 16.2%, relative risk 1.18 (95% CI 1.04–
1.34).(18) The lower target is also associated with a lower incidence of severe ROP but at 18- 
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to 24-month follow-up, the rate of severe visual disability was low with no differences 
between groups.(18) While awaiting the NeOProM final results, a saturation target of 90–
95% plus efforts to avoid hyperoxaemia is recommended.(18) This may be best achieved 
with the upper target at 94% and the high alarm set at 95%.(6) 
Case detection  
Programs for detecting ROP are well established in most of the developed nations. These 
programs provide information on the population of babies needing treatment, and how this 
population is changing over time.(19) This information continues to be used to refine 
screening criteria, to ensure that programs are as cost effective and efficient as possible.(20) 
However, these are not “screening” programs in the true sense of the word, but are “case 
detection” initiatives. Screening would entail the use of a simple, safe, non-invasive and valid 
test which identified babies needing a “gold standard” diagnosis. (19) Aside from issues with 
nomenclature, there are many practical challenges secondary to the diversity of disease. 
Broadly these issues fall into 2 categories: (1) which babies should be screened, and (2) how 
the babies should be screened.(21) Further ROP screening challenges in need of resolution 
include ensuring that the manpower needed to perform the ROP examinations is available, 
and validating non-clinician lead screening, for example, using remote image transfer further 
assisted by arguable levels of computerized automation.(21)Problems with screening are a 
major source of medico legal concern.(22) 
Screening guidelines vary with the characteristics of the premature population and neonatal 
intensive care practices in different countries and settings.(3) Most ROP Screening guidelines 
use BW and GA to identify infants needing examination, because these are major risk factors, 
are relatively straight forward to measure and are recorded routinely.(8) Screening cut-offs 
range from 30 to 35 weeks’ gestational age at birth and from birthweights of 1500 to 2000 g, 
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and depend on the extent and quality of neonatal intensive care available.(3) Guidelines 
should evolve according to changes in the local preterm population at risk. Infants who meet 
the screening criteria are referred for indirect ophthalmoscopy by a trained ophthalmologist. 
These eye examinations can be very painful for preterm infants, even when done by a skilled 
ophthalmologist.(23) In addition, the work load for ophthalmologists undertaking case 
detection is an enduring issue for ROP programmes.(6) In the context of high-quality 
neonatal intensive care, with existing screening criteria, only about 5–10% of infants 
examined will require treatment.(24) Also, a UK survey shows that in 1 year, 8208 infants 
had around 20 000 examinations by 152 ophthalmologists leading to 149 infants being 
treated; 55 infants were examined for every one treated, and there were 134 exams for each 
treated infant.(25) Safely decreasing the number of stressful and costly screening 
examinations would therefore be beneficial. 
Although indirect ophthalmoscopy is still considered the gold standard for detecting ROP, 
retina photography with a retina camera (Retcam) has been shown to be a reliable, accurate 
and cost-effective alternative method of ROP detection.(26-30). Another way to safely reduce 
the workload is through clinical prediction methods based on post-natal weight gain.(31-33) 
One example is the WINROP algorithm which has been used for more than 10 000 babies in 
NICUs of various countries.(3) A multicentre study of about 2000 preterm infants 
substantiated the high sensitivity (98·6%) and negative predictive value (99·7%) of this 
algorithm, which suggests that the number of screening examinations can be substantially 
reduced if WINROP is used in combination with traditional screening.(34)  
Classification 
Detected ROP is classified in zones and stages according to the International Classification of 
Retinopathy of Prematurity (ICROP) system(35). Infants are followed until ROP has 
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progressed to treatable stages or has resolved spontaneously and the retina is fully 
vascularized. The investigators of the Early Treatment for Retinopathy Of Prematurity 
(ETROP) study(36) reclassified retinopathy of prematurity into type 2 (to be followed up) 
and type 1 (requires urgent treatment).(3) Type 1 now includes a more virulent form of 
retinopathy in extremely low-birthweight babies (aggressive posterior retinopathy of 
prematurity (APROP)), which involves very central neovascularisation with plus disease.(35) 
Clinically significant ROP (CSROP) is ROP of any grade, in an area of the retina that might 
threaten sight. CSROP can be defined as ROP involving zone I, any stage 3 ROP or plus 
disease associated with any stage ROP in any zone, for practical purposes.(37)  
Treatment 
Cryotherapy (ablation of the non-vascularized retina) reduced blindness in threshold ROP by 
17% at age 10 years (70/227 in the treated group were blind, compared with 106/222 in the 
non-treated group of the CRYO-ROP study).(38-40) Prompt treatment of type one high risk 
pre-threshold ROP with laser photocoagulation (trans pupillary ablation of the non-
vascularized retina),  further improved short and long term visual outcomes, and is now 
considered the standard of care for ROP treatment.(36, 41) Early ROP screening and laser 
treatment is a resource intensive preventative strategy, but because of the high lifetime costs 
of severe visual impairment, it has been shown to be highly cost-effective in first world 
countries. (42, 43)12-13  
 A proportion of cases continue to progress despite laser treatment, and even a favourable 
early outcome may not mean normal vision.(6) Therefore other  ROP treatment modalities 
such as lens-sparing vitrectomy(44) to preserve vision in early retinal detachment (stage 4) 
and intravitreal anti-VEGF injections are considered. A randomised controlled trial (BEAT-
ROP) compared laser therapy to an intravitreal injection of 0,625mg bevacizumab in infants 
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with severe Zone I or posterior Zone II ROP and showed that the bevacizumide group 
required fewer retreatments before 54 weeks post menstrual age (4/70 (6%) bevacizumab 
versus 19/73 (26%) laser (OR 0.17 (95% CI 0.05 to 0.53) P = 0.002)).(45) However the 
benefit was confined to infants with Zone I disease and the study had several serious 
limitations.(46-48) In addition the dose, safety and long term outcome of bevacizumab has 
not been established in pre-term infants.(6) 
The local setting and rationale for this dissertation 
South Africa has an infant mortality rate of 53/1000 live births and has become part of the 
‘third epidemic of ROP’.(49) As described above the ‘third epidemic of ROP’ is attributed to 
both an increase in premature infant survival (the cause of the ‘second epidemic’) and poor 
oxygen management (the cause of the ‘first epidemic’) in neonatal intensive care units 
(NICUs). Due to these oxygen management inadequacies in middle-income country NICUs, 
more mature infants than in high-income NICUs may be at risk and require screening.(10, 19, 
50-52)  
An estimated 16 000 infants in South Africa are at risk of ROP and require screening each 
year.(49, 53) In 1995, ROP accounted for 10.6% of blindness in children in schools for the 
blind in South Africa.(54) The reported ROP prevalence among infants with birth weights 
less than 1500g in South African academic centres remain low, with the prevalence of any 
ROP ranging from 16.3-24.5% and clinically significant ROP (CSROP) ranging from 1.56-
4.4%.(37, 55-57) Those with sight threatening ROP requiring treatment range from 0.6-
2.9%.(53) 
The first South African guideline for the prevention, screening and treatment of ROP was 
published in 2013.(49) It recommends the screening of infants with a GA<32weeks or a 
BW<1500g. Since larger middle-income country infants (GAs: 32-35weeks; BWs: 1500g-
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2000g) may be at risk of ROP, screening of infants with birth weights up to 2000g with 
additional features associated with an increased risk of ROP (poor oxygen monitoring, 
cardiac arrest, multiple blood transfusions, exchange transfusion, severe HIE, family history 
of HIE) is also recommended. Developing screening guidelines that is appropriate for all in 
institutions within a country is challenging, since the quality of NICU care and therefore ROP 
screening requirements, are highly unit dependent.(8) Screening higher weight infants may 
not be feasible in units where resources are limited. Most level 2 hospital NICUs in South 
Africa, where larger infants are likely to be at risk of ROP, do not even have access to 
screening facilities.(49)17 On the contrary, screening larger infants in tertiary institutions in 
South Africa with high quality neonatal care may be an inappropriate application of scarce 
resource. Ideally, criteria and guidelines should be based on local evidence of the population 
of babies at risk of ROP, and these can be modified over time. 
Tygerberg Children’s Hospital (TCH) reported a prevalence of any ROP of 31.1% and 
CSROP of 7.1 % among preterm infants ventilated for respiratory distress (1986-1987)(58) 
and a prevalence of any ROP of 21.8% and CSROP of 4.4% of preterm infants treated 
exclusively with non-invasive ventilation in the first week of life (2009-2010).(37) Only 
1.5% of the latter cohort required laser therapy and no screened infants with BWs greater 
than 1250 g had CSROP. The results from these subgroup analyses are instructive but 
insufficient to inform local screening policy and resource allocation. A focused analysis of 
the existing TCH ROP screening database is needed to determine optimal screening criteria 
for retinopathy of prematurity at TCH and to explore the workload implications of using 
different BW and GA cut-off values. This work will set a platform for on-going surveillance 
and further research towards cost-effective intervention and scarce resource distribution. 
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ABSTRACT [235 words] 
Background 
High-income country ROP Screening guidelines are not appropriate for middle-income 
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countries and screening requirements may vary even between units within one city. This 
study aimed to determine optimal ROP screening criteria, and its workload implications, for 
Tygerberg Children’s Hospital (TCH), South Africa. 
Methods 
This cross-sectional study included premature infants screened for ROP, at TCH (1 January 
2009 to 31 December 2014). Logistic regression for prediction and classification were 
performed. Predictors were birth weight (BW) and gestational age (GA). Endpoints were 
clinically significant ROP (CSROP) and Type 1 ROP (T1ROP).  
Results 
Among the 1104 eligible infants, 33% had ROP (CSROP=9%; T1ROP=2.45%). All T1ROP 
infants received laser therapy. The number of screening examinations was inversely 
correlated with GA and BW. The number needed to screen to identify one infant needing 
treatment was 41 (entailing 83 examinations, four screening hours, one technician and three 
doctors). Screening infants with a GA of ≤28weeks and BW of <1000 g would have detected 
all infants with T1ROP, but missed two outliers with CSROP. These outliers would only be 
detected with a GA of ≤32 weeks or BW<1500g. 
Discussion 
Detection of infants with T1ROP is resource intensive. Larger infants require screening to 
include a few outliers, but they require fewer examinations than smaller infants.  
Conclusion 
Making local screening criteria narrower on the basis of a limited evidence base may be 
dangerous. Larger infant risk factors for CSROP need to be researched. 




FULL MANUSCRIPT  [3009 words] [tables and figures – 339 words] 
Introduction 
Retinopathy of prematurity (ROP) has an estimated global incidence of 20 000 infants per 
year.[1] South Africa (SA) joined the ‘third epidemic of ROP’ which is attributed to both 
increasing  premature infant survival and poor oxygen management in neonatal intensive care 
units (NICUs). [2] Oxygen management inadequacies in middle-income country NICUs lead 
to larger infants being at risk than in high-income countries.[3-5]  
In SA an estimated 16 000 infants are at risk of ROP and require screening each year[2,6] In 
1995, ROP accounted for 10.6% of  blindness in schools for the blind. [7] The ROP 
prevalence among infants with birth weights less than 1500g in tertiary hospitals in SA 
remains low (any ROP  16.3-24.5%,  clinically significant ROP (CSROP) 1.56-4.4%,.[8-11] 
and  sight threatening ROP 0.6-2.9%.[6]) 
The first SA ROP guideline was published in 2013.[2] It recommends the screening of infants 
with a gestational age (GA) of less than 32weeks and a birth weight (BW) of less than 1500g, 
as well as larger infants (GAs: 32-35weeks; BWs: 1500g-2000g) with an increased risk of 
ROP. 
Developing screening guidelines that are appropriate for all in institutions within a middle-
income country is challenging, since ROP screening requirements are dependent on NICU 
quality of care and this varies widely between units.[12-13] Screening higher weight infants 
may not be feasible in units where resources are limited. Most secondary level hospital 
NICUs in SA, where larger infants are likely to be at risk of ROP, do not even have access to 
screening facilities.[2] In contrast, screening larger infants in SA tertiary institutions, with 
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high quality neonatal care, may be an inappropriate use of scarce resources. Ideally, ROP 
screening criteria should be based on local evidence. 
Tygerberg Children’s Hospital (TCH) reported a ROP prevalence of 31.1% (CSROP - 7.1%) 
among preterm infants ventilated for respiratory distress (1986-1987). [14] Preterm infants 
treated exclusively with non-invasive ventilation in the first week of life (2009-2010), had a 
ROP prevalence of 21.8% (CSROP - 4.4%). [11] Only 1.5% of the latter cohort required 
treatment and none with BWs greater than 1250 g had CSROP. The results from these 
subgroup analyses are instructive but insufficient to inform local screening policy and 
resource allocation. A focused analysis of the existing TCH ROP screening database was 
undertaken to determine optimal screening criteria for retinopathy of prematurity at TCH and 
to explore the workload implications of using different BW and GA cut-off values. 
Methods 
This was a cross-sectional study, based on a database analysis, of infants born in the drainage 
area of TCH, Western Cape, SA. Attending neonatologists identified premature infants 
(admitted to TCH neonatology wards) requiring ROP screening, and registered them in the 
ROP database. ROP screening activities at TCH commenced before the release of national 
screening criteria and were governed by local data and resources at the time. Infants were 
examined and staged according to the International Classification of ROP (2005 revision) by 
a trained ophthalmologist using a 28-dioptre condensing lens and indirect ophthalmoscope. 
The screening team consisted of one technician and three doctors (supervising paediatric 
ophthalmologist and two registrars in training). Retcam III imaging was performed in 
selected cases. Examination findings were recorded in hospital records and the database. 
Infants were examined from 31 weeks corrected GA (or four weeks after birth whichever is 
later). Follow-up screens were performed one to three weekly until vascularization of zone 
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three was completed or the corrected GA of 41 weeks was reached. Infants with treatable 
stages of ROP (T1ROP) received laser therapy within 72 hours of diagnosis. 
The sample size was fixed to the number of infants with information recorded in the database. 
Screening examinations with missing outcome data were excluded from the study. The 
recorded findings (zone, stage and presence of plus disease for each eye) were converted to 
binary outcome variables: Any ROP, CSROP and T1ROP. CSROP was defined as ROP 
involving zone I, any stage 3 ROP or plus disease associated with any stage ROP in any zone. 
T1ROP was defined as any stage zone one ROP with plus disease, zone one stage three with 
or without plus disease or zone two stage two or three ROP with plus disease  
Data were entered in a custom designed Microsoft Excel spreadsheet, and analysed using 
Stata 13. Ethical approval was obtained from the ethics committees of the University of Cape 
Town, Stellenbosch University, and Tygerberg Hospital. 
Results 
Between  1st March 2009 and 28th February 2014, 1104 infants were examined for ROP and 
the examination findings recorded in the ROP database at TCH. Of the 2643 ROP screening 
examinations (bookings) registered in the database 406 (15%) examination findings were 
missing, mostly due to infants not arriving for scheduled examinations (7%) or the inability 
to perform the examinations (3%) (due to poorly dilated pupils or clinical instability)(see 
figure 1).  
The median GA at birth was 28 weeks (IQR 27-29; range 24-37). 95% had a GA of less than 
32 weeks. The median BW was 930 g (IQR 820-1040; range 523 -2600).  Median GAs and 
BWs were similar across five years of screening. The median postnatal age (PNA) of the 




Figure 1: Overview of study population. 
 
infants at the first screening examination was five weeks (IQR 4-7) and the post menstrual 
age (PMA) was 33 weeks (IQR 32-35).  
 
Retinopathy of prematurity 
 
ROP (any ROP) was found in 33% of the 1104 infants with recorded screening examination 
outcomes. CSROP was found in 9% and T1ROP in 2.45% (figure one). The prevalence of 
any ROP among infants with a gestational age of less than 27 weeks was 44% (44/98) and 
CSROP 18% (18/98). Overall, the median GA was 28 weeks in infants with ROP (27 weeks 
in CSROP) and the median BW was 865 g (826 g in CSROP). Rates of ROP according to GA 
and BW categories are shown in table 1 (among the subset of 621 infants with both GA and 
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BW recorded in the database). CSROP was detected in 2 infants with a GA of greater than 32 
weeks or BW >1500g. The one infant 
Table 1. Numbers and proportions of infants developing ROP  by GA and  BW 
              group (n=621) 
Total Any ROP CSROP Type 1 ROP 
GA category 
24-25 weeks 15 8 (53%) 4 (27%) 2 (11%) 
26-27 weeks 221 77 (35%) 28 (13%) 7 (3%) 
28-29 weeks 292 88 (30%) 20 (7%) 5 (2%) 
30-32 weeks 79 14 (18%) 3 (4%) 0 (0%) 
33-37 weeks 14 4 (29%) 1 (7%) 0 (0%) 
Total 621 191 (31%) 56 (9%) 14 (2.26) 
BW category
< 600g 10 3 (30%) 2 (20%) 0 (0%) 
600 – 799g 112 49 (43%) 15 (13%) 6 (5%) 
800 – 999g 284 93 (33%) 27 (10%) 6 (2%) 
1000-1199g 171 37 (22%) 9 (5%) 2 (1%) 
1200 -1399g 34 8 (24%) 2 (6%) 0 (0%) 
>= 14 00g 10 1 (10%) 1 (10%) 0 (0%) 
Total 621 191 (31%) 56 (9%) 14 (2.26) 
had a BW of 866 g and GA of 35 weeks. Stage one zone one ROP was detected in the right 
eye only, four weeks after birth. The other had a BW of 1530 g and GA of 31 weeks. Pre-plus 
ROP was detected in zone two of the left eye at 34 weeks PMA (three weeks PNA).  
Screening cut points 
Among the 621 infants for whom both GA and BW were recorded GA was significantly 
associated with CSROP (OR 0.710 (CI 0.579 – 0.872; p = 0.001) and BW showed a trend 
(OR 0.998 (CI 0.996-0.9995; p = 0.013). Both GA and BW were predictors of CSROP and 
T1ROP (see figure two). GA was not a significantly better predictor of CSROP than BW 
(p=0.521) neither were using both GA and BW in the prediction model better than using 
either GA (p=0.412) or BW (p=0.181). A GA cut point of 30 weeks had a sensitivity of 97% 
and specificity of 9% in detecting CSROP. With this classification rule, two older infants 
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(Infant A: GA=35 and BW=866; Infant B: GA=31 and BW=1530) with CSROP would have 
been missed in the given dataset, but neither required treatment. 
 
Figure 2: ROC curves show how prematurity predicts ROP. 
 
A less sensitive cut point of older than 28 weeks would miss nine infants, one of which would 
have required treatment. At a cut point of 1200g the BW classification rule had a sensitivity 
of 96% and a specificity of 6%. With this classification rule three infants with a BW equal to 
and greater than 1200g and CSROP would have been missed but none of them required 
treatment(Infant B: GA=31 and BW=1530; Infant C: GA=28 weeks  and BW=1200g; Infant 
D: GA=28 and BW=1220). A less sensitive cut point of 1000g would have missed 12 infants 
(two with T1ROP). Table three summarizes infants missed (false negatives) when BW and 
GA cut-offs are combined and applied. Screening criteria D (GA ≤ 28weeks or BW < 1000 g) 
would have detected all infants with CSROP requiring treatment (T1ROP). However, the 
most mature infant in the dataset with CSROP that did not require intervention had a GA of 
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31 weeks and BW of 1530 g (Infant B) and would have been detected with screening criteria 
B (GA >32 weeks or BW>1500g) only. 
Table 3. Workload implications and false negatives with application different   
               screening criteria (n=621).   
 A:  
all infants 
B:  
GA ≤ 32 weeks 
& BW < 1500 g 
C:  
GA ≤ 30weeks  
& BW <1200 g 
D:  
GA ≤ 28weeks   
& BW < 1000 g 
Number of 
infants 
621 618 (99.52%) 610 (98.23%) 530 (85.35%) 
Number of 
examinations 
1385 1382 (99.78%) 1367 (98.70%) 1236 (89.24%) 
Examinations 
per infant 




56 56 (100.00%) 55 (98.21%) 54 (96.43%) 
Number  of 
infants needed 
to screen to 
detect  1 infant 
with CSROP 




detect  1 infant 
with CSROP 
25 25 (100%) 25 (100%) 23 (92%) 
Number of 
infants with 
Type 1 ROP 
14 14 (100%) 14 (100%) 14 (100%) 
Number  of 
infants needed 
to screen to 
detect  1 infant 
needing 
treatment 




detect  1 infant 
needing 
treatment 








- 0 0 0 
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Infants needing treatment 
 
Among the 1104 infants with recorded screening examination outcomes, all with T1ROP 
received laser therapy. The 27 infants (60% females) treated for ROP were 29 weeks or 1060 
g and smaller (Median GA: 27 weeks (IQR26-28; range 24-29) and median BW: 815 g (IQR 
763-940; range 640-1060)). The median PMA of the infants at the time of T1ROP detection 
was 35 weeks (IQR 33-38; range 31-43) and the PNA was seven weeks (IQR 6-10; range 5-
15). Figure three reflects how those needing treatment changed over time, compared to those 
with CSROP and any ROP. 11/27 (41%) infants were treated during 2012. Any ROP and 
CSROP gradually increased over the study period from 14% to 48% and 4% to 14%. T1ROP 
had a baseline of 2% with a peak in 2012 (11/234 (5%) and returned to baseline in 2013. 
 
 
Figure 3: Number of infants with ROP at TCH, 2009-2014. 
Work load implications 
1104 infants required 2237 screening examinations. The median number of examinations per 
infant was two (IQR 1-3; range 1-11) with 26% (287/1104) having one examination only and 
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95% requiring less than six examinations. The median number of examinations for infants not 
needing treatment (T1ROP) was two IQR: 1-3; range: 1-10) compared with six examinations 
(IQR: 4-9; range: 1-11) for treated infants. Thirteen infants (48% (13/27)) had reached the 
criterion for treatment at the first examination. However, the complete management of those 
treated involved four or more examinations in the majority of infants (74 % (20/27) (figure 
one).The number needed to screen to identify one infant needing treatment was 41. Screening 
41 infants entailed 83 examinations, four screening hours, one technician and three doctors.  
The number of examinations required was inversely correlated with GA and BW (spearman 
correlation coefficient -0.20 and -0.27; p<0.001). Table three shows the workload 
implications of applying different screening criteria (Option B to D) to the subset of infants 
with both GA and BW recorded (Option A). The tighter the screening criteria the smaller the 
number of infants to be screened but also the higher the screening examinations per infant. 
Therefore the workload, expressed as the total number of examinations, does not decrease 
proportionately to the number of infants screened. For example, the screening criteria in table 
three option D are GA≤28weeks or BW<1000 g. Narrowing the screening criteria to option D 
will lead to 14% reduction (6 less infants) in the number to be screened to detect one infant 
needing treatment, but only 11% (not 14%) reduction (11 less examinations) in the number 
examinations required to detect one needing treatment. Such a reduction in screening criteria 
would have decreased the workload by 91 less infants to be screened (149 less examinations) 
at the expense of missing two infants with CSROP.  
Discussion 
The prevalence of CSROP among infants with GAs less than 27 weeks at birth was 18% 
(18/98). Comparison with the ROP burden elsewhere is difficult, because of the substantial 
variability in study designs, gestational ages of infants, survival rates and treatments used. 
VSSELS001: ROP Screening Criteria and Work Load Implications at TCH 
61 
 
Severe ROP prevalence estimates from population-based studies ranged from 5-35% among 
high-income countries with similar NICUs. [15] The terms low-, middle-, and high-income 
countries does not always equate to the quality of care in every NICU in a particular country. 
[13] In countries such as SA, India and Brazil, the standard of care may vary widely between 
individual NICUs. Zin and colleagues showed that in Rio de Janeiro the better NICUs were 
able to use narrower guidelines than other units in the same city. [12] The prevalence of 
T1ROP in this middle-income city ranged from 2.1% -7.8% among NICUs.[12]  The TCH 
T1ROP prevalence of 2.45%  compares with the estimate at the lower end of the range, which 
was measured at the Rio de Janeiro federal government research institute. 
As expected, the smaller and younger the infants, the higher the rates of ROP (table one). A 
significant number of infants older than 32 weeks and 1200g and larger were examined. 
These infants had additional risk factors and therefore a higher yield of any ROP. However, 
few of them had CSROP and none required treatment.  One infant with CSROP had a BW of 
1530g and another a GA of 35 weeks. However, when BW and GA are taken into account 
simultaneously, as in the SA national ROP screening guideline (GA≤32 or BW<1500), [2] no 
infants with CSROP requiring follow-up fell outside the screening criteria. Also neither of the 
two more mature infants mentioned reached the criteria for laser treatment. This indicates 
well established neonatal care at TCH and that narrower guidelines may be applicable for this 
specific unit.  
When planning ROP screening services it must be kept in mind that it is the immature and 
sick infants that require the most work.[12] In this study most larger infants required only one 
or two examinations. Including more mature infants in the screening programme does not 
increase the workload to the same extent as screening the very immature infants.     
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Screening Criteria D (GA≤28weeks or BW<1000 g) would have detected all infants needing 
treatment. Screening Criteria D plus referral of all infants at increased risk of ROP might 
have included the two more mature infants with outlying measurements. However, making 
guidelines narrower, on a relatively small evidence base, should be undertaken with caution. 
[13] Further investigation towards specific risk factors, or reasons for referral, is required in
this cohort of infants. In addition, research is required to determine whether using this lower 
GA and BW plus a “sickness” criterion (risk factors) would be an effective and efficient 
method to include the outliers. For example, prediction methods based on GA, BW and post-
natal weight gain (WINROP, ROPScore, and CHOP ROP) are employed to reduce ROP 
screening workload in high-income settings. Poor generalizability limits its use. [15-16] Another 
tool has been developed by Binbaum, which can also be used in more mature infants at risk 
for ROP in countries with developing neonatal care systems. 
In SA accurate GA estimates are not routinely available. GA in our study population was 
based on last normal menstrual date, early ultrasound or the new Ballard score calculation at 
birth. BW was as good as GA in predicting CSROP and using GA in addition to BW was not 
better at predicting CSROP. However, as was illustrated above with infant B in the dataset, 
using GA when it is available acts as a safety net to include those with high BW for GA 
(outliers). 
Zin and colleagues showed that NICUs with a <80% survival rate of infants with a 
BW<1500g should screen infants with a GA≤35 weeks and BW≤1500g, and that NICUs with 
a survival rate of ≥80% could adopt narrower screening criteria of GA<32 weeks and 
BW≤1500g. [12] The TCH survival rate of infants with a BW<1500g gradually increased from 
2009 to 2014 and was 90% on average during the study period (personal communication). 
We also showed that screening infants with GA<32 weeks and BW≤1500g is appropriate in a 
NICU with a <1500g infant survival rate of greater than 80%.  Therefore, in third epidemic 
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settings, infant mortality rate is a useful proxy to indicate which infants should be examined. 
However, these findings need to be validated. 
The Sweden ROP register (SWEDROP) showed that the incidence of severe ROP did not 
change substantially over time. [15] Perhaps an increased survival balanced against improved 
neonatal intensive care can explain this. In our study the numbers seen increased over time 
and the screening programme became more efficient in detecting any ROP and CSROP over 
time. The prevalence of T1ROP was 2% each year across the study period with an exception 
of a peak of 5% in 2012. An increase of very immature infants at high risk for T1ROP plus 
the sudden increase in the numbers of very low birth weight admissions (745 in 2012 and 801 
in 2013 as opposed to 626 in 2011 and 632 in 2010) can explain the peak. An improvement in 
overall neonatal care may explain the return to the norm in 2013.  
Study limitations 
Incomplete data limit the data analysis and interpretation in this study. The exact ROP 
screening programme coverage is not known, but it appears to be insufficient. Not all infants 
<1500g were screened. Infants ≥1200g were screened only if they had additional risk factors 
for ROP. A significant proportion, 15% (405/2670), of the examinations had missing 
outcomes and was excluded from analyses. Either GA or BW were not recorded for 44% 
(483/1104) of infants, however exploratory analysis revealed that these values were missing 
at random. Among the 621 infants (54%) with complete data, a small number required 
treatment. This may explain why the ROC curves were not very smooth and why we were 
unable to detect statistical differences between BW and GA in predicting risk of ROP. 
Improved routine data collection is needed for audit purposes and to establish the ROP 
program coverage.  
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Further studies are required to determine whether more mature infants should be screened 
routinely, or if the screening should be based on risk scores, in resource limited settings. 
Short and long term visual outcomes of infants are not recorded in the database and this  
requires further study to guide scarce resource allocation. Digital imaging of the retina is 
employed at TCH ROP screening ward rounds, but its role in ROP screening workload 
reduction is yet to be established. 
Conclusions 
Unnecessary ROP screening examination should be avoided since it is resource intensive, 
requires specially trained ophthalmologists, and is stressful for infants. In addition, neonatal 
management is continually changing, so screening criteria should be revised accordingly. 
Local audit is an essential component. However local guidelines should ideally be based on 
prospective studies.  
At TCH no infants needing treatment were larger than 1060 g or older than 29 weeks, and no 
infant requiring follow-up for CSROP fell outside the current national screening criteria of 
GA less than 32 weeks and BW less than 1500g. However, making the local screening 
criteria narrower on the basis of a limited evidence base may be dangerous. More mature 
infants require less screening examinations than smaller infants, therefore modest broadening 
of current local inclusion criteria and screening infants >32 weeks at increased risk of ROP, 
should not result in an unmanageable workload. More research is required to develop 
screening criteria for the identification of more mature infants at risk of ROP in resource 
limited settings.  
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Appendix A: Abbreviations and Glossary 
 
BW:  Birth Weight 
CSROP: Clinically Significant ROP 
EUS:   Early Ultra Sound 
GA:  Gestational Age 
LNMD: Last Normal Menstruation Date 
MPH:  Master of Public Health 
PMA:  postmenstrual age  
PNA:  postnatal age  
ROP:  Retinopathy of Prematurity  
TCH:   Tygerberg Children’s Hospital 
T1ROP: Type 1 ROP 
UCT:   University of Cape Town 
 
Threshold ROP: Zone I or II, with 5 contiguous or 8 cumulative clock hours of stage 3  
disease and plus disease 
Pre-threshold ROP: Zone I or Zone II, stage 3 disease or Zone II, stage 2 disease with plus  
disease 
Clinically Significant ROP: ROP involving zone I, any stage 3 ROP or plus disease 
associated with any stage ROP in any zone 
Type 1 Pre-threshold ROP: Zone I, any stage ROP with plus disease (plus is ≥2 quadrants 
in the  
ETROP Study) 
Zone I, stage 3 ROP with or without plus disease 
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Appendix B: ROP staging and grading system 
Visser L, Singh R, Young M et al. Guideline for the prevention, screening and treatment of retinopathy of prematurity (ROP).S Afr Med J 
2013;103(2):116-125. 
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Appendix C: TCH routine ROP screening examination form
Visser L, Singh R, Young M et al. Guideline for the prevention, screening and treatment of retinopathy of prematurity (ROP).S Afr Med J 
2013;103(2):116-125. 
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Appendix E: University of Stellenbosch study ethics approval 
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Appendix G: South African Medical Journal Author Guidelines 
South African Medical Journal Author Guidelines 
Accepted manuscripts that are not in the correct format specified in these 
guidelines will be returned to the author(s) for correction, and will delay 
publication. 
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Named authors must consent to publication. Authorship should be based on: (i) substantial 
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revision for important intellectual content; or (iii) approval of the version to be published. 
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Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or 
parent or guardian) gives informed written consent for publication. The patient should be 
shown the manuscript to be published. Refer to www.icmje.org. 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and 
reader preferences. 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 
tables or illustrations, are usually observations or research of relevance to clinical medicine 
and related fields. References should be limited to no more than 15. Please provide a 
structured abstract not exceeding 250 words, with the following recommended 
headings: Background, Objectives, Methods, Results, and Conclusion. 
Scientific letters will be considered for publication as shorter Research articles. 
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, 
will be subjected to the SAMJ peer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, for publication, should be about 400 words with only one illustration 
or table, and must include a correspondence address. 
Forum articles must be accompanied by a short description (50 words) of the affiliation 
details/interests of the author(s). Refer to recent forum articles for guidance. Please provide 
an accompanying abstract not exceeding 150 words. 
Book reviews should be about 400 words and must be accompanied by the publication 
details of the book. 
Obituaries should be about 400 words and may be accompanied by a photograph. 
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Guidelines must be endorsed by an appropriate body prior to consideration and all conflicts 
of interest expressed. A structured abstract not exceeding 250 words (recommended sub-
headings: Background, Recommendations, Conclusion) is required. Sections and sub-
sections must be numbered consecutively (e.g. 1. Introduction; 1.1 Definitions; 2. etc.) and 
summarised in a Table of Contents. References, appendices, figures and tables must be kept 
to a minumum. 
Guidelines exceeding 8 000 words will only be considered for publication as a supplement to 
the SAMJ; the costs of which must be covered by sponsorship or advertising. The Editor 
reserves the right to determine the scheduling of supplements. Understandably, a delay in 
publication must be anticipated dependent upon editorial workflow. 
  
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in 
doubt, refer to 'uniform requirements' -www.icmje.org. Manuscripts must be provided 
in UK English. 
Qualification, affiliation and contact details of ALL authors must be provided in the 
manuscript and in the online submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) 
and haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units 
should be preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. 
Greater/smaller than signs (> and 40 years of age'. The same applies to ± and º, i.e. '35±6' 
and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
General formatting The manuscript must be in Microsoft Word or RTF document format. 
Text must be single-spaced, in 12-point Times New Roman font, and contain no 
unnecessary formatting (such as text in boxes, with the exception of Tables). 
 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should 
provide consent to republication obtained from the copyright holder. 
Tables may be embedded in the manuscript file or provided as 'supplementary files'. 
They must be numbered in Arabic numerals (1,2,3...) and referred to consecutively in the 
text (e.g. 'Table 1'). Tables should be constructed carefully and simply for intelligible data 
representation. Unnecessarily complicated tables are strongly discouraged. Tables must be 
cell-based (i.e. not constructed with text boxes or tabs), and accompanied by a concise title 
and column headings. Footnotes must be indicated with consecutive use of the following 
symbols: * † ‡ § ¶ || then ** †† ‡‡ etc. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
Figure legends: Fig. 1. 'Title...' All illustrations/figures/graphs must be of high 
resolution/quality: 300 dpi or more is preferable, but images must not be resized to 
increase resolution. Unformatted and uncompressed images must be attached individually 
as 'supplementary files' upon submission (not solely embedded in the accompanying 
manuscript). TIFF and PNG formats are preferable; JPEG and PDF formats are accepted, but 
authors must be wary of image compression. Illustrations and graphs prepared in Microsoft 
Powerpoint or Excel must be accompanied by the original workbook. 
 
REFERENCES 
References must be kept to a maximum of 15. Authors must verify references from 
original sources. Only complete, correctly formatted reference lists will be 
accepted. Reference lists must be generated manually and not with the use of reference 
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Organization,[2] and others.[3,4-6] All references should be listed at the end of the article in 
numerical order of appearance in the Vancouver style (not alphabetical order). Approved 
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first three names should be given followed by et al. First and last page, volume and issue 
numbers should be given. 
Wherever possible, references must be accompanied by a digital object identifier 
(DOI) link and PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are 
encouraged to use the DOI lookup service offered by CrossRef. 
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